




RealRate

PHARMACEUTICAL 2021

Ionis Pharmaceuticals INC
Rank 266 of 394

IONIS



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Ionis Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Ionis Pharmaceuticals INC compared to the market average is the variable Comprehensive Net Income, increasing the Economic Capital Ratio by 33% points. The greatest weakness of Ionis Pharmaceuticals INC is the variable Stockholders Equity, reducing the Economic Capital Ratio by 75% points.

The company's Economic Capital Ratio, given in the ranking table, is 205%, being 51% points below the market average of 256%.

Input Variable	Value in 1000 USD
Assets, Current	2,130,707
Cost of Goods Sold	11,947
Intangible Assets	27,937
Liabilities, Current	583,250
Liabilities, Non-Current	424,046
Other Assets	50,034
Other Compr. Net Income	39,699
Other Expenses	896,801
Other Liabilities	539,112
Other Net Income	47,040
Other Revenues	729,264
Property and Equipment	181,077
Research and Development	0
Selling, General and Administrative Expense	354,322

Output Variable	Value in 1000 USD
Assets	2,389,755
Liabilities	1,546,408
Expenses	1,263,070
Revenues	729,264
Stockholders Equity	843,347
Net Income	-486,766
Comprehensive Net Income	-466,916
BaseVar	3,007,618
ECR before LimitedLiability	70%
Economic Capital Ratio	205%